[Progresses in pretransplant conditioning strategies].
Reduction of pretransplant conditioning intensity since the late 1990s has resulted in an increased incidence of relapse, although the number of transplantations has dramatically increased. In the 2000s, pretransplant conditioning was intensified again using drugs with less non-hematological toxicity. For myeloid malignancies, intravenous busulfan (ivBu), which has lesser toxicity than its oral formulation, was introduced. Its myeloablative dose can be safely administered to many patients, including the elderly. Fludarabine-ivBu combination is reported to be comparable or even better than conventional myeloablative conditioning regimens, such as Bu-Cy or TBI-Cy, for those 50 years and older. The cumulative incidence of early NRM post-transplant in patients in remission was more or less comparable to those undergoing the Seattle regimen consisting of Flu+TBI 2 Gy. Incorporating novel drugs into conditioning regimens may further reduce toxicity, particularly for patients not in remission.